Charles E. Sparks, M.D.

Charles E. Sparks, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 608
Rochester, NY 14642

Office: (585) 275-8236
Fax: (585) 756-5337

Research Bio

Apo B exists as B48 and B100 produced through a novel posttranscriptive mechanism of apo B mRNA editing producing protein products of differing size with differing metabolisms. The goal of our research is to understand apo B triglyceride-rich lipoprotein (TRL) assembly contrasting B100 and B48 synthetic pathways. McArdle RH-7777 cells (McA) have provided many useful insights into inherent differences in B100 and B48 in TRL biogenesis. Recent studies indicate that B100-TRL assembly occurs by lipidation of conformationally "acceptable" B100. B48 undergoes initial lipidation similar to B100 followed by neutral lipidation of the precursor high density lipoprotein particle (B48-HDL) to form B48-TRL. More than 70% of the triglyceride (TG) fatty acids (FA) arise from cytosolic, stored TG through a process involving lipolysis/reesterification. Lipolyzed FAs, possibly through acylation reactions with PL intermediates, traverse the ER membrane by unknown means prior to fusion with B48-HDL. Unlike B100, that is synthesized and rapidly secreted by rat hepatocytes (RH), there is a kinetically distinct pool of B48 that has a long cellular retention time. We hypothesize that this pool may provide a ready supply of B48-HDL as a precursor for the rapid assembly of TRL via a later assembly step. In cells that make predominantly B48, such as intestine, the cellular pool of B48 allows TRL secretion to occur without a requirement for de novo apo B synthesis. We recently identified a novel protein factor, an apo B secretion enhancer (BSE), whose expression correlates with apo B mRNA abundance in McA cells transfected with BSE. Apo B mRNA abundance, however, does not correspond with a proportional increase in apo B secretion. Studies explore the role of BSE in the observed changes in apo B mRNA stability/transcription. Apo B degradation studies address the non-proportional secretory rate. A phospholipid (PL)-dependent pathway for the stimulation of apo B secretion by BSE is suggested as BSE is homologous with betaine homocysteine methyltransferase (BHMT), a methylation enzyme. An hypothesis explored is that, apart from its ability to stabilize apo B mRNA, an ER form of BSE may provide newly synthesized phosphatidylcholine (PC) via phosphatidylethanolamine (PE) methylation of phosphatidylserine (PS) and increased supply of PL may be a mechanism for the enhancing secretion of apo B.



Importance of the research is related to the role of apo B in lipid transport and as a factor associated with risk of arterial disease. Additional research focuses on the role of apo B as a risk factor in developing heart attacks, strokes, and in recurrent heart attacks in human populations.

Awards & Honors

Secretarial Appointee. Department of Veterans Affairs Medical Research Service Merit Review Subcommittee for Endocrinology (Chair: Endocrinology-A Review Board, Fall 2003, Spring & Fall 2004) 2002 - 2005
Co-Chair. Thrombogenic Factors and Recurrent Coronary Events Symposium, Perugia, Italy 1998
Co-Chair. National Symposium Meeting, American Diabetes Association, Lipoproteins, Diabetes and Atherosclerosis. 1988
Invited Speaker. Gordon Research Conference on Atherosclerosis: "Is intestinal apo B a determinant for lipoprotein recognition?" 1981
Conferee. Lipid Metabolism and Atherosclerosis, 1978, '79, '80, '81, '84, '86, '88, '90, '92, '96, '00, '04 Gordon Research Conference, Kimball Union Academy, Meriden, NH 1978 - 2004
Individual Research Service Award Grantee, National Institutes of Health 1975 - 1977
Chief Resident in Pathology, University of Pennsylvania 1974 - 1975

Recent Journal Articles

Showing the 5 most recent journal articles. 92 available »

2012 Sep
Sparks JD, Sparks CE, Adeli K. "Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia." Arteriosclerosis, thrombosis, and vascular biology. 2012 Sep 0; 32(9):2104-12. Epub 2012 Jul 12.
2012 Aug
Sparks CE, Sparks JD. "Hepatic steatosis and VLDL hypersecretion." Current opinion in lipidology. 2012 Aug 0; 23(4):395-7.
2012 Jul
Corsetti JP, Gansevoort RT, Bakker SJ, Navis G, Sparks CE, Dullaart RP. "Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein." Metabolism: clinical and experimental. 2012 Jul 0; 61(7):996-1002. Epub 2012 Jan 05.
2011 Mar 11
Sparks JD, Chamberlain J, O'Dell C, Khatun I, Hussain MM, Sparks CE. "Acute suppression of apo B secretion by insulin occurs independently of MTP." Biochemical and biophysical research communications. 2011 Mar 11; 406(2):252-6. Epub 2011 Feb 18.
2010 Oct
Sparks JD, Cianci J, Jokinen J, Chen LS, Sparks CE. "Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B." American journal of physiology. Gastrointestinal and liver physiology. 2010 Oct 0; 299(4):G980-9. Epub 2010 Jul 22.

Current Appointments

Professor Emeritus - Department of Pathology and Laboratory Medicine (SMD) - Primary

Specialties

Clinical Pathology/Laboratory Medicine - American Board of Pathology

Education

MD | Medicine | Jefferson Medical College1968
BS | Biochemistry | Mass Inst Technology1963

Post-Doctoral Training & Residency

Fellowship in Biochemistry at Medical College of Pennsylvania Hospital07/01/1976 - 06/30/1977
Fellowship in Cardiopulmonary Medicine at University of Pennsylvania07/01/1975 - 06/30/1976
Residency in Clinical Pathology at Hospital of the University of Pennsylvania07/01/1972 - 06/30/1975
Internship in Medicine at New York Hospital/Cornell Medical Center07/01/1968 - 06/30/1969